The Food and Drug Administration today approved the first generic albuterol sulfate inhaler to treat and prevent bronchospasms in patients with asthma or reversible obstructive airway disease. “Metered dose inhalers like these are known as complex generics, which are traditionally harder to copy because of their complex formulation or mode of delivery,” said FDA Commissioner Stephen Hahn, M.D. “As a result, too many complex drugs lack generic competition even after patents and exclusivities no longer block generic approval. Supporting development and approval of generic copies of these complex medicines so that these products can get to patients has been a major focus of our efforts to improve competition and access and to lower drug prices.”

Related News Articles

Headline
Sens. Patrick Leahy, D-Vt., and Steve Daines, R-Mont., who cosponsored legislation that repealed the McCarran-Ferguson antitrust exemption for commercial…
Headline
Today, UnitedHealth Group announced a jaw-dropping $6 billion in earnings in a single quarter, but not enough has been said about a big contributor to these…
Blog
Today UnitedHealth Group announced a jaw-dropping $6 billion in earnings in a single quarter. But not enough has been said about a big contributor to these…
Headline
Over 1.5 million people selected a 2021 health plan through the federally facilitated marketplace between Feb. 15 and June 30 during the special…
Headline
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights yesterday held a hearing on surging drug prices and…
Headline
Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research…